Celebrating the discovery of mutated CALR
MPN Research Foundation is proud to celebrate the 10-year anniversary of the identification of CALR as a common driver of MPNs. We funded early work that discovered this MPN driver mutation. Learn more >
MPNRF by the numbers
$ 0 M
Total donated dollars
invested in research
Researchers supported
Countries with
supported research
Projects funded

What is

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is
polycythemia vera

Polycythemia vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

What is

Myelofibrosis (MF)

MF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF
Patients, clinicians, researchers, and the biotech and pharma industries all have critical roles to play in advancing MPN research and are all important members of the MPNRF community.
Connect with us to be part of our coordinated effort to find new treatments — and eventually cures — for MPNs.

and Caregivers

Every patient experience is unique and provides new clues for researchers and clinicians.


In our 24-year history, MPNRF has contributed to some of the most influential MPN research discoveries.


Engage with us to ensure that new therapies have the maximum impact on patient outcomes and quality of life.

Download our Voice of the Patient report

Ready to do more?

Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

Stay connected

Invest in MPN research

Your investment supports doctors and researchers around the world who are dedicated to finding cures for MPNs.


Join the community
Be the first to know about the latest news and advancements for ET, PV, and MF. Sign up to receive our newsletters and alerts.

Recent news

  • Patients and Caregivers Play an Active Role in MPN Research

    MPN NEWS | March 18, 2024

    Today, it is essential for patients to be involved with research and drug developers as they progress through the various stages of bringing a new therapy to market. MPN Research Foundation (MPNRF) is committed to ensuring that patient participation is more than a ticked box for drug approval. We actively work to incorporate the patient… Read More »Patients and Caregivers Play an Active Role in MPN Research


    UK Study Details Skin Cancer Risks for MPN Patients

    MPN NEWS | March 15, 2024

    Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January 2024 issue of the journal Blood reports on just how serious the risks might be, specifically among patients living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). And… Read More »UK Study Details Skin Cancer Risks for MPN Patients


    Understanding who develops which MPN and why

    MPN NEWS | March 15, 2024

      Jyoti Nangalia, MBBS, PhDWellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals. Most of them don’t acquire characteristics of myeloproliferative neoplasms (MPNs). The question is why do some people with the mutation develop an MPN while others don’t. Researchers from the Wellcome… Read More »Understanding who develops which MPN and why